TVGN (Tevogen Bio Holdings) OCF Margin %: 0.00% (As of Mar. 2026)


TVGN Tevogen Bio Holdings Inc TVGN
10 GF Score
Price $7.00
! 4 Warning Signs
View Full Analysis

What is Tevogen Bio Holdings OCF Margin %?

Tevogen Bio Holdings TVGN -27.98% 10 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TVGN with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 958 Biotechnology companies, Tevogen Bio Holdings ranks worse than 104384.03% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Tevogen Bio Holdings's Cash Flow from Operations for the three months ended in Mar. 2026 was $-2.73 Mil. Tevogen Bio Holdings's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Tevogen Bio Holdings's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Tevogen Bio Holdings's current OCF Yield % is -39.80%.

The historical rank and industry rank for Tevogen Bio Holdings's OCF Margin % or its related term are showing as below:


TVGN's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Tevogen Bio Holdings OCF Margin % Related Terms

Tevogen Bio Holdings OCF Margin % Historical Data

* Premium members only.

The historical data trend for Tevogen Bio Holdings's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tevogen Bio Holdings OCF Margin % Chart

Tevogen Bio Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00 0.00 0.00

Tevogen Bio Holdings Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TVGN
10GF Score
Tevogen Bio Holdings Inc TVGN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tevogen Bio Holdings OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Tevogen Bio Holdings's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-12.329/0
= %

Tevogen Bio Holdings's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.734/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Tevogen Bio Holdings (TVGN) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tevogen Bio Holdings and its competitors. According to the industry distribution chart, Tevogen Bio Holdings ranks #999999 out of 958 companies in the Biotechnology industry.
Is Tevogen Bio Holdings' OCF Margin % too high?
Tevogen Bio Holdings' current OCF Margin % is 0.00%. Based on the distribution chart, Tevogen Bio Holdings ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tevogen Bio Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tevogen Bio Holdings' OCF Margin % compare to DARE and BOLD?
According to the Biotechnology industry distribution chart, Tevogen Bio Holdings ranks #999999 out of 958 companies for OCF Margin %. This places Tevogen Bio Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tevogen Bio Holdings and its competitors. Tevogen Bio Holdings's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tevogen Bio Holdings stock overvalued right now?
Tevogen Bio Holdings (TVGN) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Tevogen Bio Holdings' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Tevogen Bio Holdings (TVGN), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tevogen Bio Holdings Business Description

Address 15 Independence Boulevard, Suite 210, Warren, NJ, USA, 07059
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
10GF Score

Get the complete analysis for TVGN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price